Kardigan is a clinical-stage cardiovascular biotech built by the MyoKardia leadership team, and the stock now asks investors to underwrite three parallel root-cause programs, a wearable data platform, and a related-party milestone structure, all at once. The central question is whether $1.6 billion of market value is a fair price for a company with zero revenue and its first true data print in the first half of 2027.
The quarter's defining event is the Prolaio milestone amendment, signed with the company's own CEO and CMO on May 1, 2026. It converted the original trial-based earnout into up to $200 million of valuation-threshold payments. The schedule runs through May 2032, and the vesting triggers are market-cap based rather than clinical. The mechanism is direct: the two executives now hold a contractual claim that grows when the stock appreciates, which aligns their interests with public holders while layering a transferable payout structure on top of a small-cap equity story.
The tension is that the same quarter shows the cost side of parallel clinical execution, with research spending up 57% year over year. The net loss widened to $116 million even after a $43.5 million non-cash fair-value credit on the amended Prolaio milestones. That credit is a paper gain born of the company's own market-cap jump, and stripping it out exposes a much deeper underlying operating loss. The balance sheet is the reassuring part: cash and investments stood at $660.7 million at the end of June, which is ample on paper. But the burn tells the other side of the story. The company burned $107 million in operations over the first half of 2026, and the burn trajectory is steepening rather than flattening.
The data window that resolves most of the debate arrives in the first half of 2027, when topline results from KINSHIP-DCM, KATALYST-AV, and KARDINAL-ASH land roughly together. Until then, the stock prices a portfolio of probabilities rather than evidence.